Compare GameStop Corp. (GME) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Sanofi SA — how do they compare? GameStop Corp. trades at $22.34 (market cap $9.99B), while Sanofi SA trades at $43.76 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 10.4× GameStop Corp.'s market cap, and Sanofi SA pays a 5.54% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GME | SNY | |
|---|---|---|
Market Cap | $9.99B | $103.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $52.34 |
52-Week Low | $19.94 | $41.33 |
Enterprise Value | $5.96B | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.43, up 1.82% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million, marking a significant turnaround from prior losses. Recent news highlights a partnership with Uber Eats and a proposed eBay acquisition as strategic growth catalysts.
The outlook is mixed; fundamentals show improving profitability and a robust balance sheet with $4.77 billion cash, but revenue declines and competitive pressures from digital game distribution pose risks. Analyst sentiment is cautious with only 16.7% buy ratings. Key opportunities include EBITDA guidance exceeding $600 million for 2026, while execution risks around the eBay bid and industry shifts remain headwinds.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
